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Abstract
Introduction: Limited data suggest mild hypernatremia may be related to lower intracranial pressure (ICP) in
patients with traumatic brain injury (TBI). The practice at the study center has been to use hypertonic saline (HTS)
to generate a targeted serum sodium of 145 to 155 mEq/l in patients with TBI. The purpose of this study was to
determine the relationship between serum sodium values and ICP, and to evaluate the acute effect of HTS on ICP.
Methods: A retrospective review of patients who were admitted to the trauma ICU for TBI, had an ICP monitor placed,
and received at least one dose of HTS between January 2006 and March 2011 was performed. Data were collected for
up to 120 hours after ICP monitor placement. The primary outcome was the relationship between serum sodium and
maximum ICP. Secondary outcomes were the relationship between serum sodium and the mean number of daily
interventions for ICP control, and the acute effect of HTS on ICP during the 6 hours after each dose. Linear regression
was used to analyze the primary outcome. Analysis of variance on ranks and repeated measures analysis of variance
were used to evaluate the number of interventions and the acute effect of HTS on ICP, respectively.
Results: Eighty-one patients were enrolled with mean ± standard deviation age of 36 ± 15 years and median Glasgow
Coma Scale score of 7 (interquartile range, 4 to 7). A total of 1,230 serum sodium values (range, 118 to174 mEq/l) and
7,483 ICP values (range, 0 to 159 mmHg) were collected. There was no correlation between serum sodium and maximum
ICP (R2 = 0.0052). The overall mean ± standard deviation number of interventions for elevated ICP per day was 4.2 ± 2.9,
2.9 ± 2.0, and 2.6 ± 2.3 for patients with a mean serum sodium of < 145, 145 to 155, and > 155 mEq/l, respectively (P <
0.001). Regarding the acute effect of HTS on ICP, there was no statistical difference in mean ICP compared with baseline
during hours 1 through 6 following HTS doses (baseline, 13.7 ± 8.4 mmHg; hour 1, 13.6 ± 8.3 mmHg; hour 2, 13.5 ± 8.8
mmHg; hour 3, 13.3 ± 8.7 mmHg; hour 4, 13.4 ± 8.7 mmHg; hour 5, 13.4 ± 8.3 mmHg; hour 6, 13.5 ± 8.3 mmHg; P = 0.84).
Conclusions: Serum sodium concentrations did not correlate with ICP values. These results warrant further
evaluation and possible reassessment of sodium goals for ICP management in patients with TBI.
Introduction
Traumatic brain injury (TBI) is the leading cause of mor-
bidity and mortality in young adults [1]. When treating
TBI, optimal intracranial pressure (ICP) control (that is, <
20 mmHg) and an adequate cerebral perfusion pressure of
50 to 70 mmHg are goals associated with lower mortality
[2]. While mannitol has long been a mainstay of ICP man-
agement, the use of hypertonic saline (HTS) has more
recently gained increasing support. This increased usage is
likely because of a perceived decrease in adverse effects in
comparison with mannitol such as excessive volume loss
and rebound ICP elevation [3]. However, the Brain
Trauma Foundation guidelines for the management of
TBI note that the strength of the current literature does
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not substantiate a formal recommendation on the use of
HTS to lower ICP [2].
Small clinical studies in patients with TBI have sug-
gested that the acute effects of HTS administration on
ICP may be equivalent to or in some cases more substan-
tial and longer lasting than mannitol [4,5]. These studies
seem to support the use of HTS for acute ICP manage-
ment in patients with TBI. However, some centers use a
somewhat different approach in using HTS to target
serum sodium of 145 to 155 mEq/l in the hope of provid-
ing a continuous ICP-lowering effect. This is based on
limited retrospective data suggesting that targeting a
serum sodium concentration of 145 to 155 mEq/l in
patients with TBI may correlate with a reduction in ICP
[6]. More data on the safety and efficacy of this approach
are clearly needed.
At the study institution HTS is administered every 6
hours to target a serum sodium goal of 145 to 155 mEq/l.
Our study group hypothesized that targeting serum
sodium concentrations of 145 to 155 mEq/l would corre-
late with lower ICP values. To test this hypothesis, we per-
formed a retrospective review with the following specific
aims: to define the relationship between serum sodium
concentration and ICP; to determine the relationship
between serum sodium concentration and the number of
daily interventions for intracranial hypertension in patients
with TBI; and to determine the acute change in ICP
following a HTS bolus.
Materials and methods
Study design and patient population
This retrospective review was approved by the Institu-
tional Review Board of the University of Tennessee
Health Science Center and the Regional Medical Center
at Memphis. All consecutive patients admitted to the
Regional Medical Center at Memphis for TBI between
January 2006 and March 2011 who received at least one
dose of HTS as documented in the medication profile
(Meditech, Medical Information Technology, Westwood,
MA, USA) were identified for screening. Those who met
the following criteria based on retrospective review of the
medical record were enrolled in the study: age ≥ 18 years,
treatment with HTS confirmed by medication adminis-
tration records, and ICP monitor placement. Patients
were excluded if their neurologic insult was not due to
TBI. Owing to the retrospective nature of the study, all
treatment occurred as part of routine patient care, and
the requirement for informed consent was waived.
Data from the medical record and a trauma registry
(NTRACS, version 3.0; Digital Innovation, Forest Hill,
MD, USA) were used to determine patient demographics,
Injury Severity Score, daily Glasgow Coma Scale (GCS)
score, mechanism of trauma resulting in TBI (for example,
fall, motor vehicle collision, assault, pedestrian struck,
gunshot wound), type of trauma (blunt vs. penetrating),
neurosurgical procedures (for example, ventriculostomy,
craniectomy), number and type of medical interventions
per day for ICP management (for example, HTS, mannitol,
sedation, neuromuscular blockade), hourly ICP, hourly
cerebral perfusion pressure, laboratory information (for
example, serum creatinine, serum sodium), hospital length
of stay, duration of mechanical ventilation, and in-hospital
mortality. Data pertaining to ICP management were col-
lected for up to 120 hours after ICP monitor placement
for each patient.
Treatment
Upon admission to the Regional Medical Center at Mem-
phis, patients with severe TBI had ICP monitors
(Camino®; Integra LifeSciences Corporation, Plainsboro,
NJ, USA) placed at the discretion of a neurosurgery
attending physician. Owing to the retrospective nature of
the study, data pertaining to the location of the ICP
monitor in relation to the area of injury were not always
available and therefore these data were not recorded.
Following the ICU standard of care, ICP and cerebral
perfusion pressure data were recorded by nursing staff
on an hourly basis. Nurses are trained to evaluate ele-
vated ICP values, and therapy for intracranial hyperten-
sion is only implemented if the value is not a spurious
result (for example, not due to coughing). No formal pro-
tocol is used for the treatment of intracranial hyperten-
sion. However, neurosurgeons in the ICU have a
standard approach that includes monitoring the serum
sodium concentration every 6 hours and using HTS to
raise it above 145 mEq/l. Most patients received 150 ml
of 3% HTS intravenously over 2 hours; however, patients
who received 150 ml of 7.5% HTS intravenously over
2 hours or continuous intravenous infusion of 3% HTS
were also reviewed for this study.
Primary and secondary outcomes
The primary outcome was the relationship between
serum sodium and the corresponding maximum ICP.
Secondary outcomes included the relationship between
the serum sodium and the number of therapeutic inter-
ventions for increased ICP management, and the acute
effect of HTS boluses on ICP.
Definitions
Three methods were used to evaluate the primary out-
come. First, each serum sodium value was matched with
the highest corresponding ICP recorded before the next
serum sodium was measured. The highest ICP value was
chosen because intracranial hypertension is clinically
important and warrants therapy in TBI patients. This
matching was repeated for each serum sodium measure-
ment while the ICP monitor was in place. Missing ICP
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data were replaced with the last recorded ICP measure-
ment. Second, the change in serum sodium was matched
with the change in ICP. To determine the change in
serum sodium, the value prior to a HTS bolus was sub-
tracted from the serum sodium value following that
bolus. The ICPs measured in the same hour as each
serum sodium value were used to determine the corre-
sponding change in ICP. These values were chosen
because they best represent the ICP that corresponds to
the serum sodium. Third, to account for interpatient
variability, serum sodium and the corresponding maxi-
mum ICP for each individual patient were also deter-
mined. Linear regression was used to identify any
relationship between serum sodium and ICP for each of
the three methods.
To evaluate the secondary outcome of relating serum
sodium to the number of interventions for intracranial
hypertension, patients were divided into three groups
based on their mean daily serum sodium: < 145 mEq/l,
145 to 155 mEq/l, and > 155 mEq/l. The mean number
of interventions per day on days 1 to 5 was compared
among these three groups. The following treatments
were included as an intervention: HTS infusion, mannitol
infusion, sedation or analgesia given by continuous infu-
sion, neuromuscular blocker (NMB) infusion, pentobar-
bital infusion, or acute hyperventilation (partial pressure
of carbon dioxide < 35 mmHg). Any single dose of HTS,
mannitol, or NMB was counted as one intervention.
Continuous infusions of HTS or NMB were counted as
one intervention. Acute hyperventilation was documen-
ted as an intervention if an arterial blood gas was avail-
able. If more than one arterial blood gas was drawn on
any given day for a single patient, only one partial pres-
sure of carbon dioxide < 35 mmHg counted as an inter-
vention for that patient. If a patient’s serum sodium was
not available on a given day, interventions for that day
were excluded from the analysis. Neurosurgical interven-
tions were not included in this analysis, because it was
not possible to relate the timing of these procedures to
the ICP readings, as details were not consistently
available.
To evaluate the secondary outcome of the acute effect of
HTS on ICP, only HTS boluses were included. The base-
line ICP was defined as the measurement immediately
prior to a HTS bolus. The baseline ICP was compared
with the ICP from each hour following the HTS bolus.
Each bolus was classified as having a positive or negative
response on the ICP. A positive response was deemed as
any reduction in ICP (negative change in ICP) within the
first hour following a bolus. A negative response was
either no change or an increase in ICP within the first
hour. Patients’ responses to HTS boluses were also evalu-
ated based on the number of doses that resulted in a posi-
tive response or a negative response. Ultimately, patients
were placed into one of two categories based on their
response to all boluses. Poor responders (n = 41) demon-
strated a positive response following 0 to 49% of HTS
boluses. Good responders (n = 31) demonstrated a positive
result following 50 to 100% of HTS boluses.
Statistical analysis
Continuous variables were compared using Student’s t
test for normally distributed variables or the Wilcoxon
rank-sum test for non-normally distributed variables.
Proportions were compared using the chi-squared test.
Linear regression was used to evaluate the relationship
between serum sodium levels and corresponding maxi-
mum ICP. Linear regression was also used to analyze the
relationship between change in serum sodium and the
corresponding change in ICP. Analysis of variance on
ranks was used to compare the number of daily interven-
tions among the three groups categorized by serum
sodium. Multiple pairwise comparisons were made using
Dunn’s method. Repeated-measures analysis of variance
was used to evaluate the acute effect of HTS on ICP over
the 6 hours following a bolus. All statistical analyses were
performed using SigmaPlot, version 11.0 (Systat Software
Inc., San Jose, CA, USA). Data are presented as mean ±
standard deviation, median (interquartile range), or pro-
portions as indicated. P < 0.05 was considered statistically
significant.
Results
A total of 81 patients with TBI were enrolled into the
study. Baseline demographics are presented in Table 1.
Demographics were representative of the patient popula-
tion with TBI commonly seen in the study ICU [7-9].
Sixty-eight patients (84%) received 3% sodium chloride
boluses only. The remaining patients received a combi-
nation of 3% and 7.5% sodium chloride boluses, and/or
continuous infusions of 3% sodium chloride.
A total of 1,230 serum sodium values (sodium range,
118 to 174 mEq/l) and 7,483 ICP values (ICP range, 0 to
159 mmHg) were collected. Figure 1 shows patients’
serum sodium concentrations and their corresponding
maximum ICP. Overall, no significant correlation was
seen (R2 = 0.0052). There was no significant correlation
between serum sodium and maximum ICP for subgroups
of patients with a baseline ICP < 25 mmHg or ≥ 25
mmHg (R2 = 0.0003 and 0.0134, respectively). Further-
more, no correlation between these variables was seen
when patients were grouped by GCS score (GCS 3 to 8,
R2 = 0.0045; GCS 9 to 12, R2 = 0.0010; GCS 13 to 15, R2 =
0.3084). The association between the change in serum
sodium concentration and change in ICP is depicted in
Figure 2. The correlation between these two variables was
poor (R2 = 0.0111). Finally, correlations of serum sodium
and ICP analyzed for each patient were poor, as indicated
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by the number of patients in each R2 quartile (Table 2).
These results were similar for the entire patient group or
when analyzed by subgroups that might affect ICP control
(Table 2).
The mean number of daily interventions per patient
based on serum sodium concentration is depicted in
Table 3. Interventions included administration of 388
HTS doses, 133 mannitol doses, 54 pentobarbital doses,
332 sedation doses, 198 NMB doses, and 118 acute
hyperventilation procedures. There was a statistically
significant difference in the total number of interven-
tions over the 5 days for patients with mean serum
sodium values < 145 mEq/l when compared with either
patients with serum sodium values of 145 to 155 mEq/l
or those with values > 155 mEq/l (P < 0.05 for each)
(Table 3). Statistically significant differences were noted
on days 2, 3, and 5, but not for days 1 or 4 (Table 3).
When HTS boluses were excluded from the intervention
analyses, there was no difference in the number of inter-
ventions over the 5 days among the sodium groups <
145 mEq/l, 145 to 155 mEq/l, or > 155 mEq/l (P =
0.934), or at any other point during the study period
(day 1, P = 0.415; day 2, P = 0.401; day 3, P = 0.055; day
4, P = 0.64; day 5, P = 0.805).
The acute effect of HTS on ICP was evaluated for 322
HTS boluses in 72 patients. Overall, the mean ± standard
deviation ICP did not significantly change in the 6 hours
following a HTS bolus (baseline, 13.7 ± 8.4 mmHg; hour 1,
13.6 ± 8.3 mmHg; hour 2, 13.5 ± 8.8 mmHg; hour 3,
13.3 ± 8.7 mmHg; hour 4, 13.4 ± 8.7 mmHg; hour 5,
13.4 ± 8.3 mmHg; hour 6, 13.5 ± 8.3 mmHg; P = 0.84).
When poor responders were analyzed separately, no signif-
icant change was again noted (baseline, 12.5 ± 6.1 mmHg;
hour 1, 13.2 ± 6.6 mmHg; hour 2, 13 ± 6.7 mmHg; hour 3,
12.6 ± 5.8 mmHg; hour 4, 12.5 ± 5.6 mmHg; hour 5,
12.6 ± 6.1 mmHg; hour 6, 12.5 ± 5.7 mmHg; P = 0.16).
Good responders demonstrated a statistical trend
toward lower ICP values following a HTS bolus (baseline,
16.1 ± 11.2 mmHg; hour 1, 14.3 ± 10.8 mmHg; hour 2,
14.3 ± 11.7 mmHg; hour 3, 14.8 ± 12.3 mmHg; hour 4,
15.1 ± 12.5 mmHg; hour 5, 15 ± 11.3 mmHg; hour 6,
15.4 ± 11.4 mmHg; P = 0.068). Figure 3 shows the change
in ICP following a HTS bolus for all patients, poor respon-
ders and good responders. Demographics for patients in
the poor and good responder groups were not different
except for the median (interquartile range) Injury Severity
Score (poor responders, 30 (25 to 38); good responders,
38 (29 to 43); P = 0.029).
Discussion
Effects of targeting mild hypernatremia
The current study is the largest to evaluate the correla-
tion of serum sodium and ICP in patients with TBI.
These retrospective results did not demonstrate a corre-
lation between serum sodium and ICP. This finding was
consistent when patient data were analyzed using multi-
ple different methods and for multiple subgroups. The
administration of HTS did not consistently result in
Table 1 Baseline demographics and clinical
characteristics
Characteristic Value
Age (years) 36 ± 15
Serum creatinine (mg/dl) 1 ± 0.4
Serum sodium (mEq/l) 139 ± 7
Baseline intracranial pressure (mmHg) 19 ± 11.5
Glasgow Coma Scale 7 (4 to 7)
Injury Severity Score 34 (25 to 41)
Male sex 65 (80%)
Caucasian 54 (67%)
Mechanism of injury
Blunt trauma 77 (95%)
Penetrating trauma 4 (5%)
Traumatic brain injury cause
Motor vehicle collision 47 (58%)
Fall 17 (21%)
Assault 6 (7%)
Pedestrian struck 6 (7%)
Gunshot wound 5 (6%)
Isolated traumatic brain injury 30 (37%)
Reactive pupils 52 (64%)
Midline shift 38 (47%)
Craniotomy/craniectomy 46 (58%)
Ventriculostomy 31 (38%)
In-hospital mortality 33 (41%)
Length of stay (days)
ICU 20 ± 17
Hospital 23 ± 21
Duration of mechanical ventilation (days) 13 ± 10
Data presented as mean ± standard deviation, median (interquartile range), or
number (%) of patients. n = 81.
Figure 1 Scatter plot for correlation between serum sodium
and maximum intracranial pressure for all patients.
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increases in serum sodium as seen in Figure 2. This
would suggest a reason for the lack of significant
changes in ICP. It is unknown whether a more substan-
tial increase in serum sodium would result in further
decreases in ICP. Based on Figure 2, even serum sodium
increases of > 2 mEq/l did not consistently result in a
decrease in ICP.
Statistically, there were fewer mean interventions for
ICP control in patients with mean serum sodium > 145
mEq/l. However, there was only a statistical difference on
three of the 5 days studied. This finding is not clinically
significant, as it is expected that patients with serum
sodium < 145 mEq/l would receive more HTS doses in
an attempt to achieve the goal for serum sodium (145 to
155 mEq/l). In fact, when HTS doses were excluded from
the analyses, no difference in the number of interventions
among groups was seen at any point in the study period.
An alternative explanation is that serum sodium > 145
mEq/l truly did have a beneficial effect in decreasing the
number of interventions. Overall, we feel that this is unli-
kely because there was no correlation between ICP and
serum sodium in any of the analyses.
The poor correlation between ICP and serum sodium
found in the current study is perplexing when compared
with data from Qureshi and colleagues. They retrospec-
tively evaluated the use of continuous infusion 3% saline to
target a serum sodium between 145 and 155 mEq/l, and
they found that increased serum sodium concentrations
correlated with lower ICP in the eight patients with TBI
(R2 = 0.91, P = 0.03) and five with postoperative edema
(R2 = 0.82, P = 0.06) [6]. Overall, the mean ICP was
reduced by 6.9 ± 2.4 mmHg, suggesting that continuous
infusion of HTS could reduce ICP in a select group of
patients. Although baseline ICP values were not specifically
Figure 2 Scatter plot for correlation between change in serum sodium and change in intracranial pressure for bolus doses of 3%
sodium chloride.
Table 2 Individual patient serum sodium and intracranial pressure correlations
Patient group Patients in each R2 quartile
< 0.25 0.26 to 0.5 0.51 to 0.75 > 0.75
All patients 63 (81%) 9 (11%) 6 (8%) 0 (0%)
Those with craniotomy/craniectomy 33 (77%) 6 (14%) 4 (9%) 0 (0%)
Those with ventriculostomy 28 (90%) 2 (7%) 1 (3%) 0 (0%)
Those with continuous infusion hypertonic saline 10 (100%) 0 (0%) 0 (0%) 0 (0%)
Those without ventriculostomy, craniotomy/craniectomy, or continuous infusion hypertonic saline 19 (90%) 2 (10%) 0 (0%) 0 (0%)
Data presented as n (%). Each serum sodium measurement was matched to the corresponding intracranial pressure to calculate individual R2 values for every
patient. Patients were divided into different groups based on whether or not they received various treatments and/or procedures during the study period (for
example, craniectomy, ventriculostomy, continuous infusion hypertonic saline). The number of patients per group falling into each R2 quartile is provided.
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defined, the mean ICP reported prior to HTS administra-
tion (14.2 ± 4.2 mmHg) is lower than the mean baseline
ICP of 19.1 ± 11.5 mmHg seen in the current study. Addi-
tionally, the current study evaluated significantly more
patients with TBI and the majority of patients received
HTS boluses (84%) rather than continuous infusions.
Roquilly and colleagues retrospectively investigated the
use of 20% HTS in 50 TBI patients. They used a continu-
ous infusion to target serum sodium of 145 to 155 mEq/l
[10]. Mean ICP significantly decreased by the first hour
from 31 ± 9 to 21 ± 8 mmHg (P < 0.05). Mean serum
sodium significantly increased within the first 4 hours
from 140 ± 4 to 144 ± 4 mEq/l (P < 0.05). Although no
statistical evaluation was performed to correlate serum
sodium with ICP, it appears that ICP decreased as serum
sodium increased. While this study focused on TBI, the
treatment of these patients was different from that in the
current study due to the fact that they used HTS as a
third-line agent after mannitol and sodium thiopental by
continuous infusion, while the current study used HTS as
the first-line agent.
Conversely, data from Shackford and colleagues support
the current study. They prospectively compared the use of
continuous infusion of 1.6% HTS (n = 18) versus lactated
Ringer’s solution (n = 16) in patients with TBI [11]. There
was no difference in mean ICP between groups, and the
number of daily interventions for ICP management was
higher on days 1 and 5 for patients who received HTS.
The authors attributed these findings to a trend for lower
admission GCS scores in the HTS group. Similarly, Qure-
shi and colleagues evaluated the use of continuous infu-
sion of 2 to 3% saline (n = 36) versus normal saline (n =
48) in patients with TBI [12]. In-hospital mortality was
higher in patients who received HTS (odds ratio, 3.1; 95%
confidence interval, 1.1 to 10.2), despite no difference in
admission GCS scores or the number of interventions for
ICP management between groups.
Overall, the four previous studies in this area and the
current study show mixed results. Two studies suggested
that increasing the serum sodium improved ICP control
(total n = 58) and two did not (total n = 113). The fifth
study suggested that continuous infusion of HTS may be
Table 3 Number of interventions for intracranial
hypertension
Mean serum sodium P value
< 145 mEq/l 145 to 155 mEq/l > 155 mEq/l
Day 1 4.35 ± 2.33 4.31 ± 2.02 2.00 ± 0 0.354
Day 2 4.16 ± 2.73 2.67 ± 1.39 3.00 ± 0 0.033
Day 3 5.12 ± 3.97 2.91 ± 1.82 3.17 ± 3.49 0.018
Day 4 3.60 ± 3.50 3.41 ± 2.59 2.33 ± 2.00 0.527
Day 5 3.19 ± 2.44 1.84 ± 0.90 2.67 ± 1.53 0.043
Total 4.20 ± 2.91 2.95 ± 1.97 2.62 ± 2.25 < 0.001
Data presented as mean ± standard deviation number of interventions per
day, providing a summary of the mean number of interventions for
intracranial pressure control on days 1 to 5. Patients were divided into three
groups based on their mean serum sodium value on each day of the study
period. For each day, statistical comparisons were performed for the number
of interventions required in each group.
Figure 3 Mean change in intracranial pressure for 6 hours following a hypertonic saline bolus. Poor responders demonstrated a positive
response to 0 to 49% of hypertonic saline boluses. Good responders demonstrated a positive response to 50 to 100% of hypertonic saline
boluses.
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detrimental. As such, these results call into question the
targeting of mild hypernatremia for ICP control.
Acute effects of hypertonic saline on intracranial pressure
The more commonly reported use of HTS in TBI has
been for acute treatment of elevated ICP. Regarding the
acute effects of HTS boluses in the current study, this
therapy did not result in statistically significant reduc-
tions in ICP overall. However, there was a group of
patients that seemed to respond. These findings are
important given that poor ICP control is associated with
increased mortality and effective pharmacologic manage-
ment is a key part of therapy [13,14]. The results of this
study are significant because using HTS for manage-
ment of intracranial hypertension is not yet clearly
defined in the Brain Trauma Foundation guidelines [2].
The data are also mixed for bolus administration of
HTS. Several studies reported an acute decrease in ICP
by 5 to 15 mmHg using HTS boluses [4,5,15-19]. In the
current study there was a less profound effect with no
significant change in the ICP following a HTS bolus.
However, the good responder group did demonstrate a
reduction in ICP that approached significance (P =
0.068). It is important to note that the methods between
studies have not been uniform and patients have varied
by type and severity of illness. The best method of HTS
administration has obviously yet to be determined. This
is especially true in light of studies that have highlighted
the dangers of hypernatremia from continuous infusions
of HTS, including an increased risk of death in ICU
patients [20-22].
Strengths and limitations
The current study has strengths and limitations. The ret-
rospective design and the lack of a control group are the
most significant limitations. Owing to the current stan-
dard of care in our institution, it was not possible to find
a control group that did not receive HTS. The inability to
relate the time of neurosurgical interventions is proble-
matic due to the effect such procedures could have on
ICP. Unfortunately, the retrospective nature of the study
only allowed for collection of whether or not a patient
underwent a procedure. However, collection of these
data was consistent with the American Brain Injury Con-
sortium methods used in clinical trials. Another limita-
tion relates to the documentation of ICP. Each ICP value
is simply a snapshot over the course of each hour. Also,
hospital policy allowed nurses to have a 1-hour time
window to administer a HTS dose relative to the docu-
mented time in the medication administration record.
These are pragmatic issues inherent to any retrospective
study in this field.
The primary strength of the study is the large sample
size (n = 81). This is the largest study to date
examining the use of HTS in this fashion. Another
strength of the study was the relatively homogeneous
patient population, including only patients with TBI.
Finally, while there was not a formal treatment proto-
col for administration of HTS, there was a relatively
uniform approach to treatment of TBI by the neuro-
surgeons in the ICU.
Conclusion
Serum sodium values of critically ill patients with TBI
do not correlate with ICP - although patients with
serum sodium values < 145 mEq/l required more inter-
ventions for intracranial hypertension. Patients who had
a good acute response to HTS boluses trended toward a
decrease in ICP following each dose compared with
poor responders. Targeting a serum sodium value of
145 to 155 mEq/l requires further evaluation.
Key messages
• Serum sodium values do not correlate well with
ICP in patients with TBI treated with HTS.
• Achieving serum sodium values between 145 and
155 mEq/l may decrease the number of daily inter-
ventions required to manage elevated ICP.
• HTS boluses did not significantly decrease ICP
overall.
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